Navigation Links
Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus

d, double-blind, placebo-controlled Phase 2 trial, 96% (351/364) elected to enter the 24-week open-label extension phase of the trial, and 92% (321/351) of those who entered completed it. Of those completing the extension phase, 78% (250/321) continue to receive LymphoStat-B in a long-term continuation study. The trial began in October 2003.

"We are encouraged that nearly all of the patients who completed the 52- week Phase 2 study chose to continue treatment in the 24-week extension phase," said William W. Freimuth, M.D., Ph.D., Vice President, Clinical Research -- Immunology, Rheumatology and Infectious Diseases, Human Genome Sciences. "Many of these patients began treatment more than three years ago and continue on treatment today. This provides us with a substantial body of data on the long-term effects of LymphoStat-B."

About the Phase 2 Trial Results

The primary objectives of the Phase 2 study were to evaluate the safety, tolerability and efficacy of LymphoStat-B plus standard of care, versus placebo plus standard of care. A total of 449 patients with active SLE were randomized to receive one of three different doses of LymphoStat-B or placebo (1, 4 or 10 mg/kg) administered intravenously over a 52-week treatment period, in addition to standard-of-care therapy. In the extension phase, all placebo patients received LymphoStat-B at a dose of 10 mg/kg, while patients in the LymphoStat-B 10 mg/kg treatment arm continued on the 10 mg/kg dose, and patients in the 1 mg/kg and 4 mg/kg LymphoStat-B treatment arms were offered the choice of continuing on the same dose or receiving LymphoStat-B at a dose of 10 mg/kg.

In June 2006, HGS reported the 52-week data from the Phase 2 trial of LymphoStat-B in patients with SLE. The 52-week results demonstrated that LymphoStat-B significantly reduced disease activity versus placebo in patients with serologically active SLE, exhibited clinically relevant biological activity, and appeared safe and well t
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Testing for Human Papillomavirus
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
4. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
5. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
6. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
7. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
8. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
9. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
Post Your Comments:
(Date:8/21/2014)... , Aug. 21, 2014 Nektar Therapeutics ... Inc. today announced positive results from its Phase ... investigational, extended half-life recombinant factor VIII (rFVIII) treatment ... (Recombinant)], which met its primary endpoint in reducing ... compared to the on-demand arm. Top-line ...
(Date:8/21/2014)... -- The spinal column is one of the most delicate ... and from the brain through the column control many key ... ailment here can be life altering, and leave the victim ... their body. Though back injury and disease can have an ... options available to make things better than ever before. ...
(Date:8/21/2014)... 21, 2014 /CNW/ - Eisai Limited is pleased to support ... first-of-its-kind comic book available in Canada . ... specifically to educate children and their parents about epilepsy, the ... affecting more than 300,000 Canadians. Eisai is guided by a ... in which the patient is central – there was a ...
Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... 5, 2011 Elekta,s MOSAIQ® Oncology Information System ... No. 1 ranking in the oncology software category from ... Category Leader designation identifies top-rated vendor products in the ... for each market segment. The 2010 ...
... (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, ... at the J.P. Morgan 29th Annual Healthcare Conference in San ...   Interested parties may access a live audio ... the BioMarin website, www.BMRN.com .  A replay of the ...
Cached Medicine Technology:Elekta's MOSAIQ Oncology Information System Named Category Leader in '2010 Top 20 Best in KLAS Awards' Report 2Elekta's MOSAIQ Oncology Information System Named Category Leader in '2010 Top 20 Best in KLAS Awards' Report 3BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference 2
(Date:8/22/2014)... Beach, Florida (PRWEB) August 22, 2014 ... for Lasik in Fort Lauderdale at the most affordable ... get better eyesight through their advanced Lasik treatments. LASIK ... worldwide and the Braverman Eye Center has been delivering ... of patients live a glasses-free and contact lenses-free life ...
(Date:8/22/2014)... pain, breathing difficulties, fainting. Each year approx. 265,000 Danes ... serious illness. New research from Aarhus University and Aarhus ... as many as every fourth patient are sent ... symptoms that led to the acute hospitalisation., "Naturally, there ... at the hospital disprove that there is a serious ...
(Date:8/22/2014)... new study from Karolinska Institutet in Sweden provides insight ... touch, vision or sound from different sources and sides ... adequate movements. The findings, which are presented in the ... as a sensory ,hub, integrating various types of sensory ... types. , "The striatum is the main input structure ...
(Date:8/22/2014)... allergy is frequently confused with lactose intolerance. However, these ... body. People with lactose intolerance do not digest lactose ... In the case of the potentially much more dangerous ... milk proteins with its own IgE antibodies. , According ... in Europe suffer from a genuine milk allergy. Less ...
(Date:8/22/2014)... be able to better understand their risks of future ... with different treatments. , The findings, set out in ... are based on the experience of more than 2,000 ... cancer over a period of more than 40 years. ... lymphoma who receive certain types of chemotherapy or radiotherapy ...
Breaking Medicine News(10 mins):Health News:Braverman Eye Center Now Offers Lasik Treatment in Fort Lauderdale at the Most Affordable Fee 2Health News:Many patients are discharged without a diagnosis 2Health News:The striatum acts as hub for multisensory integration 2Health News:Scientists uncover why major cow milk allergen is actually allergenic 2Health News:Scientists map risk of premature menopause after cancer treatment 2
... Support the Long Term Mental Health Needs ... SAN DIEGO, Oct. 24 As the hundreds of,thousands San ... what,happened and deal with the stress of the situation. These ... those directly and,indirectly affected. In the days, weeks and months ...
... Support The Cause In A Variety Of Ways ..., ... the,team,s First Annual Breast Cancer Awareness Night on Friday, October ... Joe Louis Arena. Doors open,at 6 p.m. for the 7:30 ... Hockey Fights Cancer month when all NHL players wore special ...
... MONTREAL, Oct. 24 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX ... to,announce a new two-phase strategy to have a ... for its lead product candidate, the,Hemaseel(R)HMN fibrin sealant, ... This "First-Patient-In" objective is a major milestone ...
... M. Foley, MD,of Memorial Sloan-Kettering Cancer Center in ... University of Utah School of Medicine, received the ... 2007 at the 9th,Annual Josefina Magno Conference on ... of palliative care, the science of pain and,symptom ...
... reduced toxicity, studies find, , , WEDNESDAY, Oct. 24 (HealthDay ... to the standard two-drug regimen used for head and ... reducing the toxicity, two new studies report. , The ... increased survival in both studies and more than doubled ...
... Norway October 24, 2007 - The use of ... increased incidence of reproductive endocrine disorders in both men ... the effects of withdrawal from two common AEDs, carbamazepine ... and female AED users. , The study finds ...
Cached Medicine News:Health News:San Diego Wildfires Mental Health Fund 2Health News:San Diego Wildfires Mental Health Fund 3Health News:Red Wings Host Breast Cancer Awareness Night 2Health News:Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials 2Health News:Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials 3Health News:Two Physicians Recognized for Work in Pain and Symptom Management 2Health News:Three Chemo Drugs Better Than Two for Advanced Head/Neck Cancers 2Health News:Three Chemo Drugs Better Than Two for Advanced Head/Neck Cancers 3
... WatchMate system is designed to protect a ... and becoming lost or injured. Such residents ... etc., or have suffered a head injury., ... on their wrist or ankle, and points ...
... Smart™ Labels have a direct thermal ... Instruments Tag-it™ HF-I transponder. When processed ... text and other graphics may be ... data is programmed to the RFID ...
... a patent pending solution using Radio ... a smart label to promote patient ... wrong-site, wrong-procedure surgery. This simple to ... orthopedic surgeon with the operating room ...
... Hospitals, correctional facilities, recreational venues ... wristbands to provide automated data capture ... reducing costly and dangerous errors. RFID ... admissions wristbands at entertainment venues as ...
Medicine Products: